Activation of the cGAS–STING pathway by clofoctol through mitochondrial damage in triple-negative breast cancer
Lusheng Wang, Lijie Zheng, Xiang Yong, Zhixian Ding, Jiting Sun, Yu Tang, Kemeng Tang, Yafen Li, Jie Chen, Shuaiyong Qi, Huaiyuan Hu, Heng Tang · 2025
Read Activation of the cGAS–STING pathway by clofoctol through mitochondrial damage in triple-negative breast cancer by Lusheng Wang, Lijie Zheng, Xiang Yong, Zhixian Ding, Jiting Sun, Yu Tang, Kemeng Tang, Yafen Li, Jie Chen, Shuaiyong Qi, Huaiyuan Hu, Heng Tang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12801497.txt.
Description
Lusheng Wang and co-authors test an old antibacterial drug, clofoctol, against triple negative breast cancer in a 2025 study. This cancer form lacks the targets most breast drugs aim at, so reused drugs are prized. Computer screening first pointed to the pathways the drug might hit; cell and mouse tests then checked the guesses.
Clofoctol slowed the cancer cells' growth and spread and pushed them into arrest and death. It wrecked their power plants, spilling stress signals and a death trigger. The damage also woke an immune alarm pathway inside the cells. Tumors in mice shrank as well, the team reports, with safety checks alongside.
Catalog record
| CREATOR | Lusheng Wang, Lijie Zheng, Xiang Yong, Zhixian Ding, Jiting Sun, Yu Tang, Kemeng Tang, Yafen Li, Jie Chen, Shuaiyong Qi, Huaiyuan Hu, Heng Tang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |